Intracellular allosteric antagonism of the CCR9 receptor

Nature

Volumn 540, Issue 7633, 2016, Pages 462-465

  Oswald, Christine ^a   Rappas, Mathieu ^a   Kean, James ^a   Doré, Andrew S ^a   Errey, James C ^a   Bennett, Kirstie ^a   Deflorian, Francesca ^a   Christopher, John A ^a   Jazayeri, Ali ^a   Mason, Jonathan S ^a   Congreve, Miles ^a   Cooke, Robert M ^a   Marshall, Fiona H ^a  

^a Heptares Therapeutics Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN 2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CXCR4; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; GLUCAGON RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; VERCIRNON; CC CHEMOKINE RECEPTOR 9; CCR5 PROTEIN, HUMAN; CCX282-B; CHEMOKINE RECEPTOR CCR; CXCR4 PROTEIN, HUMAN; HETEROTRIMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; LIGAND; SULFONAMIDE;

ANTAGONISM; CELLS AND CELL COMPONENTS; CRYSTAL STRUCTURE; GENETIC ANALYSIS; GROWTH RATE; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; OPTIMIZATION; PROTEIN; TUMOR;

ALLOSTERISM; AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG RECEPTOR BINDING; HYDROGEN BOND; INTRACELLULAR MEMBRANE; MOLECULAR DYNAMICS; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; CONSERVED SEQUENCE; CYTOPLASM; DRUG DESIGN; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; MOLECULAR MODEL; MUTAGENESIS; X RAY CRYSTALLOGRAPHY;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; CONSERVED SEQUENCE; CRYSTALLOGRAPHY, X-RAY; CYTOPLASM; DRUG DESIGN; HETEROTRIMERIC GTP-BINDING PROTEINS; HUMANS; LIGANDS; MODELS, MOLECULAR; MUTAGENESIS; RECEPTORS, CCR; RECEPTORS, CCR5; RECEPTORS, CXCR4; SULFONAMIDES;

EID: 85016143647     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature20606     Document Type: Article

References (41)

1. Pease, J. E. Targeting chemokine receptors in allergic disease. Biochem. J. 434, 11-24 (2011).
2. Wilkin, T. J. & Gulick, R. M. CCR5 antagonism in HIV infection: current concepts and future opportunities. Annu. Rev. Med. 63, 81-93 (2012).
3. Vela, M., Aris, M., Llorente, M., Garcia-Sanz, J. A. & Kremer, L. Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges. Front. Immunol. 6, 12 (2015).
4. Solari, R., Pease, J. E. & Begg, M. "Chemokine receptors as therapeutic targets: why arent there more drugs?". Eur. J. Pharmacol. 746, 363-367 (2015).
5. Pease, J. & Horuk, R. Chemokine receptor antagonists. J. Med. Chem. 55, 9363-9392 (2012).
6. Wendt, E. & Keshav, S. CCR9 antagonism: potential in the treatment of inflammatory bowel disease. Clin. Exp. Gastroenterol. 8, 119-130 (2015).
7. Changeux, J. P. & Christopoulos, A. Allosteric modulation as a unifying mechanism for receptor function and regulation. Cell 166, 1084-1102 (2016).
8. Serrano-Vega, M. J., Magnani, F., Shibata, Y. & Tate, C. G. Conformational thermostabilization of the β1-adrenergic receptor in a detergent-resistant form. Proc. Natl Acad. Sci. USA 105, 877-882 (2008).
9. Robertson, N. et al. The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery. Neuropharmacology 60, 36-44 (2011).
10. Walters, M. J. et al. Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J. Pharmacol. Exp. Ther. 335, 61-69 (2010).
11. Tan, Q. et al. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 341, 1387-1390 (2013).
12. Wu, B. et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330, 1066-1071 (2010).
13. Hollenstein, K. et al. Structure of class B GPCR corticotropin-releasing factor receptor 1. Nature 499, 438-443 (2013).
14. Jazayeri, A. et al. Extra-helical binding site of a glucagon receptor antagonist. Nature 533, 274-277 (2016).
15. Tchernychev, B. et al. Discovery of a CXCR4 agonist pepducin that mobilizes bone marrow hematopoietic cells. Proc. Natl Acad. Sci. USA 107, 22255-22259 (2010).
16. Andrews, G., Jones, C. & Wreggett, K. A. An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5. Mol. Pharmacol. 73, 855-867 (2008).
17. Gonsiorek, W. et al. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist. J. Pharmacol. Exp. Ther. 322, 477-485 (2007).
18. Salchow, K. et al. A common intracellular allosteric binding site for antagonists of the CXCR2 receptor. Br. J. Pharmacol. 159, 1429-1439 (2010).
19. Lazaar, A. L. et al. SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. Br. J. Clin. Pharmacol. 72, 282-293 (2011).
20. Nicholls, D. J. et al. Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2. Mol. Pharmacol. 74, 1193-1202 (2008).
21. de Kruijf, P. et al. Nonpeptidergic allosteric antagonists differentially bind to the CXCR2 chemokine receptor. J. Pharmacol. Exp. Ther. 329, 783-790 (2009).
22. Thelen, M. Dancing to the tune of chemokines. Nature Immunol. 2, 129-134 (2001).
23. Deupi, X. & Standfuss, J. Structural insights into agonist-induced activation of G-protein-coupled receptors. Curr. Opin. Struct. Biol. 21, 541-551 (2011).
24. Tehan, B. G., Bortolato, A., Blaney, F. E., Weir, M. P. & Mason, J. S. Unifying family A GPCR theories of activation. Pharmacol. Ther. 143, 51-60 (2014).
25. Rasmussen, S. G. et al. Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 477, 549-555 (2011).
26. Kang, Y. et al. Crystal structure of rhodopsin bound to arrestin by femtosecond X-ray laser. Nature 523, 561-567 (2015).
27. Ungashe, S. et al. Aryl sulphonamides. US patent 2006/0111351A1 (2006).
28. Nugent, T. & Jones, D. T. Membrane protein orientation and refinement using a knowledge-based statistical potential. BMC Bioinformatics 14, 276-285 (2013).
29. Alva, V. et al. The MPI bioinformatics Toolkit as an integrative platform for advanced protein sequence and structure analysis. Nucleic Acids Res. 44 (Suppl. W1), W410-W415 (2016).
30. Kawate, T. & Gouaux, E. Fluorescence-detection size-exclusion chromatography for precrystallization screening of integral membrane proteins. Structure 14, 673-681 (2006).
31. Caffrey, M. & Cherezov, V. Crystallizing membrane proteins using lipidic mesophases. Nature Protocols 4, 706-731 (2009).
32. Kabsch, W. Integration, scaling, space-group assignment and post-refinement. Acta Crystallogr. D 66, 133-144 (2010).
33. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D 50, 760-763 (1994).
34. Evans, P. R. & Murshudov, G. N. How good are my data and what is the resolution? Acta Crystallogr. D 69, 1204-1214 (2013).
35. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
36. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486-501 (2010).
37. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D 66, 213-221 (2010).
38. Murshudov, G. N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D 67, 355-367 (2011).
39. Afonine, P. V. et al. Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr. D 68, 352-367 (2012).
40. Martyna, G. J., Tobias, D. J. & Klein, M. L. Constant pressure molecular dynamics algorithms. J. Chem. Phys. 101, 4177-4189 (1994).
41. Diederichs, K. & Karplus, P. A. Better models by discarding data? Acta Crystallogr. D 69, 1215-1222 (2013).